BBIL's Hepatitis B Vaccine crosses 150 million mark

Hyderabad, Oct 30 (UNI) Bharat Biotech International Limited (BBIL), the multi-dimensional Biotechnology company, specialised in product-oriented research, development and manufacturing of vaccines and bio-therapeutics, today announced that it has crossed production and delivery of more than 150 million doses of REVAC-B+TM, recombinant Hepatitis B Vaccine since its launch in October 1998.

In a statement here, BBIL Chairman and Managing Director Krishna Ella said, ''The success of REVAC-B+TM bears testimony to our solid emphasis on Research and Development to develop vaccines that carry excellent safety and efficacy profiles''.

REVAC-B+TM had been marketed and sold in more than 30 countries worldwide with manufacturing and quality standards on par with USFDA, EMEA and WHO guidelines, he said, adding the Vaccine has established an excellent safety and efficacy profile since its launch 10 years ago.

The Next Generation REVAC-Bmcf recombinant Hepatitis-B Vaccine manufactured by the compant was cost-effective and addressed the safety concerns, he added.

UNI VA MDG 1721